15.50
price up icon0.06%   0.010
after-market Dopo l'orario di chiusura: 15.50
loading
Precedente Chiudi:
$15.49
Aprire:
$15.53
Volume 24 ore:
617.69K
Relative Volume:
0.99
Capitalizzazione di mercato:
$1.09B
Reddito:
$1.23M
Utile/perdita netta:
$-214.90M
Rapporto P/E:
-3.7601
EPS:
-4.1222
Flusso di cassa netto:
$-151.25M
1 W Prestazione:
-1.40%
1M Prestazione:
+0.65%
6M Prestazione:
-35.01%
1 anno Prestazione:
-34.85%
Intervallo 1D:
Value
$15.26
$16.61
Intervallo di 1 settimana:
Value
$14.00
$17.29
Portata 52W:
Value
$10.91
$40.26

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name
Nome
Spyre Therapeutics Inc
Name
Telefono
(617) 651-5940
Name
Indirizzo
221 CRESCENT STREET, WALTHAM
Name
Dipendente
65
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SYRE's Discussions on Twitter

Confronta SYRE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SYRE
Spyre Therapeutics Inc
15.50 1.09B 1.23M -214.90M -151.25M -4.1222
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-08 Iniziato Leerink Partners Outperform
2025-03-18 Iniziato Wolfe Research Outperform
2024-09-04 Iniziato Wedbush Outperform
2024-07-16 Iniziato Evercore ISI Outperform
2024-05-02 Iniziato Robert W. Baird Outperform
2024-03-01 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-20 Iniziato BTIG Research Buy
2023-12-11 Iniziato Guggenheim Buy
2023-12-11 Iniziato Jefferies Buy
2020-05-04 Iniziato Piper Sandler Overweight
2019-03-21 Iniziato JP Morgan Overweight
2018-09-04 Downgrade Wells Fargo Outperform → Market Perform
2018-04-24 Iniziato Evercore ISI Outperform
2018-03-14 Reiterato Needham Buy
Mostra tutto

Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie

pulisher
Jun 18, 2025

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire

Jun 17, 2025
pulisher
Jun 16, 2025

Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 16, 2025
pulisher
Jun 11, 2025

California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener

Jun 09, 2025
pulisher
Jun 06, 2025

Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 02, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire

Jun 02, 2025
pulisher
May 30, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences - Eastern Progress

May 30, 2025
pulisher
May 30, 2025

Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know - sharewise

May 30, 2025
pulisher
May 30, 2025

Millennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 30, 2025
pulisher
May 30, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 30, 2025
pulisher
May 28, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conf - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts - Defense World

May 28, 2025
pulisher
May 28, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences | SYRE Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Spyre Therapeutics IBD Pipeline Updates Coming at Major June Healthcare Conferences - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Deutsche Bank AG - Defense World

May 28, 2025
pulisher
May 26, 2025

BNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 26, 2025
pulisher
May 19, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust Corp - Defense World

May 19, 2025
pulisher
May 14, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by The Manufacturers Life Insurance Company - Defense World

May 14, 2025
pulisher
May 13, 2025

How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% - Yahoo Finance

May 13, 2025
pulisher
May 10, 2025

First Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 10, 2025
pulisher
May 10, 2025

Spyre Therapeutics (NASDAQ:SYRE) Shares Up 12.6% on Earnings Beat - Defense World

May 10, 2025
pulisher
May 09, 2025

Spyre Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Spyre Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

Spyre (SYRE) Advances Clinical Trials with Strong Financial Backing | SYRE Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Spyre Therapeutics Inc Reports Q1 2025 EPS of -$0.60, Beating Estimates, Amid $44.8 Million Net Loss - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

May 08, 2025
pulisher
May 06, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Position Boosted by Tower Research Capital LLC TRC - The AM Reporter

May 06, 2025
pulisher
May 06, 2025

MetLife Investment Management LLC Has $498,000 Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - The AM Reporter

May 06, 2025
pulisher
May 06, 2025

Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World

May 06, 2025
pulisher
May 06, 2025

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57 - Defense World

May 06, 2025
pulisher
May 05, 2025

Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 - Nasdaq

May 05, 2025
pulisher
May 05, 2025

Spyre Therapeutics (SYRE) Showcases Promising IBD Treatment Data at Upcoming Conference | SYRE Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 | SYRE Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PR Newswire

May 05, 2025
pulisher
May 04, 2025

Invesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 04, 2025
pulisher
May 03, 2025

Wells Fargo & Company MN Purchases 6,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

May 03, 2025
pulisher
May 02, 2025

Spyre Therapeutics Awards 64,400 Shares in Stock Options to Strategic New Employee Hires - Stock Titan

May 02, 2025

Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Spyre Therapeutics Inc Azioni (SYRE) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Albers Jeffrey W.
Director
Oct 25 '24
Sale
36.43
300
10,929
34,060
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):